

Notice Regarding Adjustment of 340B Prices for Select Products of Xellia Pharmaceuticals (US) LLC

Xellia Pharmaceuticals (US) LLC (“Xellia”) has recalculated its 340B ceiling prices for certain products for the period 2019Q2 through 2020Q3 (the “Restatement Period”). The products impacted are listed below. The recalculation of ceiling prices results from revisions made to Medicaid price reporting for the period of 2018Q4 through 2020Q1. Xellia has asked the Office of Pharmacy Affairs (“OPA”) to post the notice to the OPA public website to ensure transparency by providing access to information regarding Xellia’s recalculation and potential overpayments by certain 340B Covered Entities for impacted Xellia products related thereto. Xellia will be communicating with and issuing refunds through its third-party logistics (3PL) agent ICS Amerisource Bergen Specialty Group (“ICS”) for 340B Covered Entities where Xellia’s data demonstrates that a 340B Covered Entity has overpaid for the impacted products during the Restatement Period. However, Covered Entities should contact Xellia directly via email at Barbara.signa@xellia.com if there are issues regarding the credit provided by ICS via wholesalers. All credits should be issued to wholesalers by May 31, 2021.

NDC11	Product Description
70594-0046-02	Vancomycin HCL 1GM
70594-0048-01	Vancomycin HCL 10GM
70594-0034-01	Daptomycin 500MG
70594-0046-02	Vancomycin HCL 1GM
70594-0048-01	Vancomycin HCL 10GM
70594-0042-03	Vancomycin RTU 1GM
70594-0046-02	Vancomycin HCL 1GM
70594-0048-01	Vancomycin HCL 10GM
70594-0046-02	Vancomycin HCL 1GM
70594-0048-01	Vancomycin HCL 10GM
70594-0048-01	Vancomycin HCL 10GM
70594-0053-01	Daptomycin 350MG
70594-0023-01	Colistimethate 150MG
70594-0023-04	Colistimethate 150MG
70594-0034-01	Daptomycin 500MG
70594-0053-01	Daptomycin 350MG